Biote Corp. shares rise 2.11% after-hours following NKGen Biotech's acquisition of NKMax.

Biote Corp. rose 2.11% in after-hours trading, with the company's stock price increase potentially influenced by the broader positive sentiment in the biotech sector. This sentiment was driven by several significant events, including NKGen Biotech's acquisition of a controlling stake in NKMax, which marks a pivotal moment in its transformation into a fully integrated, self-sustaining cell therapy company. Additionally, the healthcare sector saw increased activity with deals such as Novartis' acquisition of Tourmaline Bio for $1.4 billion, contributing to a bullish outlook for biotech stocks.